Literature DB >> 12539204

Pathogenic role of glial cells in Parkinson's disease.

Peter Teismann1, Kim Tieu, Oren Cohen, Dong-Kug Choi, Du Chu Wu, Daniel Marks, Miquel Vila, Vernice Jackson-Lewis, Serge Przedborski.   

Abstract

Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive loss of the dopaminergic neurons in the substantia nigra pars compacta (SNpc). The loss of these neurons is associated with a glial response composed mainly of activated microglial cells and, to a lesser extent, of reactive astrocytes. This glial response may be the source of trophic factors and can protect against reactive oxygen species and glutamate. Alternatively, this glial response can also mediate a variety of deleterious events related to the production of pro-oxidant reactive species, and pro-inflammatory prostaglandin and cytokines. We discuss the potential protective and deleterious effects of glial cells in the SNpc of PD and examine how those factors may contribute to the pathogenesis of this disease. Copyright 2002 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12539204     DOI: 10.1002/mds.10332

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  68 in total

1.  Exercise protects against MPTP-induced neurotoxicity in mice.

Authors:  Kimberly M Gerecke; Yun Jiao; Amar Pani; Vishwajeeth Pagala; Richard J Smeyne
Journal:  Brain Res       Date:  2010-01-29       Impact factor: 3.252

Review 2.  Microarrays in Parkinson's disease: a systematic approach.

Authors:  Renee M Miller; Howard J Federoff
Journal:  NeuroRx       Date:  2006-07

3.  Glutathione S-transferase pi mediates MPTP-induced c-Jun N-terminal kinase activation in the nigrostriatal pathway.

Authors:  Margarida Castro-Caldas; Andreia Neves Carvalho; Elsa Rodrigues; Colin Henderson; C Roland Wolf; Maria João Gama
Journal:  Mol Neurobiol       Date:  2012-04-27       Impact factor: 5.590

4.  Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.

Authors:  R Lee Mosley; Eric J Benner; Irena Kadiu; Mark Thomas; Michael D Boska; Khader Hasan; Chad Laurie; Howard E Gendelman
Journal:  Clin Neurosci Res       Date:  2006-12-06

5.  Interleukin-6 serum levels in patients with Parkinson's disease.

Authors:  Kerly Wollmeister Hofmann; Artur Francisco Schumacher Schuh; Jonas Saute; Raquel Townsend; Daniele Fricke; Renata Leke; Diogo O Souza; Luis Valmor Portela; Márcia Lorena Fagundes Chaves; Carlos R M Rieder
Journal:  Neurochem Res       Date:  2009-02-13       Impact factor: 3.996

6.  Jmjd3 is essential for the epigenetic modulation of microglia phenotypes in the immune pathogenesis of Parkinson's disease.

Authors:  Y Tang; T Li; J Li; J Yang; H Liu; X J Zhang; W Le
Journal:  Cell Death Differ       Date:  2013-11-08       Impact factor: 15.828

7.  Prokineticin-2 promotes chemotaxis and alternative A2 reactivity of astrocytes.

Authors:  Matthew Neal; Jie Luo; Dilshan S Harischandra; Richard Gordon; Souvarish Sarkar; Huajun Jin; Vellareddy Anantharam; Laurent Désaubry; Anumantha Kanthasamy; Arthi Kanthasamy
Journal:  Glia       Date:  2018-09-12       Impact factor: 7.452

Review 8.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

9.  Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration.

Authors:  Anna L Bartels; Klaus L Leenders
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

Review 10.  Epigenetic regulation of astrocyte function in neuroinflammation and neurodegeneration.

Authors:  Matthew Neal; Jason R Richardson
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-11-04       Impact factor: 5.187

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.